Allergen mimotopes

Methods

Volumn 32, Issue 3, 2004, Pages 321-327

  Riemer, Angelika ^a   Scheiner, Otto ^a   Jensen Jarolim, Erika ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Allergen; Epitope; Mimotope; Phage display

Indexed keywords

ALLERGEN; COMPLEMENTARY DNA; EPITOPE; IMMUNOGLOBULIN E; PEPTIDE LIBRARY;

AMINO ACID SEQUENCE; ARTICLE; BACTERIAL GENOME; BACTERIOPHAGE; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC SCREENING; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; MOLECULAR CLONING; PHAGE DISPLAY; PHAGEMID; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; SEQUENCE ANALYSIS; WILD TYPE;

EID: 1042287266     PISSN: 10462023     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymeth.2003.08.010     Document Type: Article

References (56)

1. Ishizaka K., Ishizaka T., Lee E.H. Physiochemical properties of reaginic antibody. II. Characteristic properties of reaginic antibody different from human gamma-A-isohemagglutinin and gamma-D-globulin. J. Allergy. 37(6):1966;336-349.
2. Johansson S.G., Bennich H. Immunological studies of an atypical (myeloma) immunoglobulin. Immunology. 13(4):1967;381-394.
3. Ravetch J.V., Kinet J.P. Fc receptors. Annu. Rev. Immunol. 9:1991;457-492.
4. Beaven M.A., Metzger H. Signal transduction by Fc receptors: the Fc epsilon RI case. Immunol. Today. 14(5):1993;222-226.
5. Jensen-Jarolim E.et al. Nonapeptides selected by phage display mimic the binding sites of monoclonal antibodies BIP1 and BIP4 on Bet v 1, the major birch pollen allergen. Int. Arch. Allergy Immunol. 118(2-4):1999;224-225.
6. Ganglberger E.et al. Allergen mimotopes for 3-dimensional epitope search and induction of antibodies inhibiting human IgE. FASEB J. 14(14):2000;2177- 2184.
7. Furmonaviciene R.et al. The use of phage-peptide libraries to define the epitope specificity of a mouse monoclonal anti-Der p 1 antibody representative of a major component of the human immunoglobulin E anti-Der p 1 response. Clin. Exp. Allergy. 29(11):1999;1563-1571.
8. Aalberse R.C., van der Gaag R., van Leeuwen J. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J. Immunol. 130(2):1983;722-726.
9. Birkner T.et al. Evaluation of immunotherapy-induced changes in specific IgE, IgG, and IgG subclasses in birch pollen allergic patients by means of immunoblotting. Correlation with clinical response. Allergy. 45(6):1990;418-426.
10. Jarolim E.et al. A long-term follow-up study of hyposensitization with immunoblotting. J. Allergy Clin. Immunol. 85(6):1990;996-1004.
11. Moverare R.et al. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy. 57(5):2002;423-430.
12. Ball T.et al. Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur. J. Immunol. 29(6):1999;2026-2036.
13. van Ree R.et al. Possible induction of food allergy during mite immunotherapy. Allergy. 51(2):1996;108-113.
14. Valenta R.et al. The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin. Exp. Allergy. 29(7):1999;896-904.
15. Singh M.B., de Weerd N., Bhalla P.L. Genetically engineered plant allergens with reduced anaphylactic activity. Int. Arch. Allergy Immunol. 119(2):1999;75-85.
16. Engel E.et al. Immunological and biological properties of Bet v 4, a novel birch pollen allergen with two EF-hand calcium-binding domains. J. Biol. Chem. 272(45):1997;28630-28637.
17. Smith A.M., Chapman M.D. Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2. Mol. Immunol. 33(4-5):1996;399-405.
18. Wiedemann P.et al. Molecular and structural analysis of a continuous birch profilin epitope defined by a monoclonal antibody. J. Biol. Chem. 271(47):1996;29915-29921.
19. Ferreira F.et al. Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. FASEB J. 12(2):1998;231-242.
20. Vrtala S.et al. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J. Clin. Invest. 99(7):1997;1673-1681.
21. Vrtala S.et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J. 15(11):2001;2045-2047.
22. Pauli G.et al. Clinical evaluation of genetically engineered hypoallergenic rBet v 1 derivatives. Int. Arch. Allergy Immunol. 118(2-4):1999;216-217.
23. van Hage-Hamsten M.et al. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. J. Allergy Clin. Immunol. 104(5):1999;969-977.
24. Visco V.et al. Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. J. Immunol. 157(2):1996;956-962.
25. Lebecque S.et al. Immunologic characterization of monoclonal antibodies that modulate human IgE binding to the major birch pollen allergen Bet v 1. J. Allergy Clin. Immunol. 99(3):1997;374-384.
26. Laffer S.et al. Molecular characterization of Bip 1, a monoclonal antibody that modulates IgE binding to birch pollen allergen, Bet v 1. J. Immunol. 157(11):1996;4953-4962.
27. van Hage-Hamsten M., Valenta R. Specific immunotherapy - the induction of new IgE-specificities? Allergy. 57(5):2002;375-378.
28. Ball T.et al. B cell epitopes of the major timothy grass pollen allergen, phl p 1, revealed by gene fragmentation as candidates for immunotherapy. FASEB J. 13(11):1999;1277-1290.
29. Focke M.et al. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J. 15(11):2001;2042-2044.
30. De Weck A.L.et al. Clinical trial of Ro 6-0787, a monovalent specific hapten inhibitor of penicillin allergy. Z. Immunitatsforsch. Exp. Klin. Immunol. 150(2):1975;138-160.
31. Richter W.et al. [Anaphylactoid reactions after dextran. I. Immunology of the pathomechanism and the hapten inhibition]. Beitr. Infusionther. Klin. Ernahr. 8:1981;54-65.
32. Valenta R.et al. The immunoglobulin E-allergen interaction: a target for therapy of type I allergic diseases. Int. Arch. Allergy Immunol. 116(3):1998;167-176.
33. Niederberger V.et al. Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations. J. Allergy Clin. Immunol. 102(4 Pt. 1):1998;579-591.
34. Niederberger V.et al. IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE. J. Allergy Clin. Immunol. 101(2 Pt. 1):1998;258-264.
35. Gajhede M.et al. X-ray and NMR structure of Bet v 1, the origin of birch pollen allergy. Nat. Struct. Biol. 3(12):1996;1040-1045.
36. Leitner A.et al. A mimotope defined by phage display inhibits IgE binding to the plant panallergen profilin. Eur. J. Immunol. 28(9):1998;2921- 2927.
37. Suphioglu C.et al. A novel grass pollen allergen mimotope identified by phage display peptide library inhibits allergen-human IgE antibody interaction. FEBS Lett. 502(1-2):2001;46-52.
38. Jensen-Jarolim E.et al. Peptide mimotopes displayed by phage inhibit antibody binding to bet v 1, the major birch pollen allergen, and induce specific IgG response in mice. FASEB J. 12(15):1998;1635-1642.
39. Ganglberger E.et al. Monovalent fusion proteins of IgE mimotopes are safe for therapy of type I allergy. FASEB J. 15(13):2001;2524-2526.
40. Jensen-Jarolim E.et al. Allergen mimotopes in food enhance type I allergic reactions in mice. FASEB J. 13(12):1999;1586-1592.
41. Smith G.P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. 228(4705):1985;1315- 1317.
42. Smith G.P., Petrenko V.A. Phage display. Chem. Rev. 97(2):1997;391-410.
43. Felici F.et al. Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector. J. Mol. Biol. 222(2):1991;301-310.
44. Cwirla S.E.et al. Peptides on phage: a vast library of peptides for identifying ligands. Proc. Natl. Acad. Sci. USA. 87(16):1990;6378-6382.
45. Devlin J.J., Panganiban L.C., Devlin P.E. Random peptide libraries: a source of specific protein binding molecules. Science. 249(4967):1990;404-406.
46. Mazzucchelli L.et al. Cell-specific peptide binding by human neutrophils. Blood. 93(5):1999;1738-1748.
47. Luzzago A.et al. Mimicking of discontinuous epitopes by phage-displayed peptides, I. Epitope mapping of human H ferritin using a phage library of constrained peptides. Gene. 128(1):1993;51-57.
48. Davies J.M., O'Hehir R.E., Suphioglu C. Use of phage display technology to investigate allergen-antibody interactions. J. Allergy Clin. Immunol. 105(6 Pt. 1):2000;1085-1092.
49. Parmley S.F., Smith G.P. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene. 73(2):1988;305-318.
50. D'Mello F., Howard C.R. An improved selection procedure for the screening of phage display peptide libraries. J. Immunol. Methods. 247(1-2):2001;191-203.
51. Barbas III C.F., Lerner R.A. Combinatorial immunoglobulin libraries on the surface of phage (phabs): rapid selection of antigen-specific Fabs. Methods: A Companion to Methods in Enzymology. 1991;119-124 Academic Press, New York.
52. Sanger F., Nicklen S., Coulson A.R. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA. 74(12):1977;5463-5467.
53. Schöll I.et al. Phage-displayed Bet mim 1, a mimotope of the major birch pollen allergen Bet v 1, induces B-cell responses to the natural antigen using bystander T-cell help. Clin. Exp. Allergy. 32(11):2002;1583-1588.
54. Meola A.et al. Derivation of vaccines from mimotopes. Immunologic properties of human hepatitis B virus surface antigen mimotopes displayed on filamentous phage. J. Immunol. 154(7):1995;3162-3172.
55. Delmastro P.et al. Immunogenicity of filamentous phage displaying peptide mimotopes after oral administration. Vaccine. 15(11):1997;1276-1285.
56. Partidos C.D. Peptide mimotopes as candidate vaccines. Curr. Opin. Mol. Ther. 2(1):2000;74-79.